Komori
KYORIN Pharmaceutical (4569) · TargetSoftened

Capital Investment to Expand Factory Facilities in the Fiscal Year Ending March 2019

First written in FY2018. 3 of 6 entries say "Raised", first in FY2019. Latest entry: FY2025.

6entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2018RaisedFY2019 – FY2020OtherFY2023RaisedFY20242018: 120182019: 120192020: 120202021: 020212022: 020222023: 120232024: 120242025: 12025
Same theme, other companies
Expansion and Rationalization of Manufacturing FacilitiesA theme 376 companies write about · 0 as a headwind · 415 as a tailwind

KYORIN Pharmaceutical moved to the "Worse" side of this theme in 2025, 2 years after the typical company in this theme (2023).

2 other companies' latest entry also says "Softened".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 182 companies compared. The sentences above are computed from all 182.Comparing 200 of the theme's 415 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025SoftenedAnnual report

    「For the fiscal year ending March 2026, we plan to spend approximately ¥4,700 million on acquisitions of fixed assets, including expanded factory facilities.」

    The plan for acquisitions of fixed assets, including expanded factory facilities, was reduced from approximately ¥6.6 billion for the fiscal year ending March 2025 in the previous disclosure to approximately ¥4.7 billion for the fiscal year ending March 2026.
  2. FY2024RaisedAnnual report

    「For the fiscal year ending March 2025, we plan to spend approximately ¥6,600 million on acquisitions of fixed assets, including expanded factory facilities.」

    The plan for acquisitions of fixed assets, including expanded factory facilities, was expanded from approximately ¥5.9 billion in the previous disclosure to approximately ¥6.6 billion for the fiscal year ending March 2025.
  3. FY2023Capital expenditure results and plan for the following fiscal yearAnnual report

    「During the current consolidated fiscal year, we made capital expenditures of ¥5,252 million. For the fiscal year ending March 2023, we plan to spend approximately ¥5.9 billion on acquisitions of fixed assets, including expanded factory facilities.」

    Capital expenditures during the year amounted to ¥5,252 million, and a plan to spend approximately ¥5.9 billion on expanded factory facilities and other projects was also disclosed.
  4. FY2020RaisedAnnual report

    「For the fiscal year ending March 2021, we plan to spend approximately ¥5.1 billion on acquisitions of fixed assets, including expanded factory facilities.」

    The plan for acquisitions of fixed assets, including factory facilities and other assets, was expanded from approximately ¥4.1 billion in the fiscal year ending March 2020 to approximately ¥5.1 billion in the fiscal year ending March 2021.
  5. FY2019RaisedAnnual report

    「For the fiscal year ending March 2020, we plan to spend approximately ¥4.1 billion on acquisitions of fixed assets, including expanded factory facilities.」

    The plan for acquisitions of fixed assets, including expanded factory facilities, was updated from approximately ¥4 billion in the fiscal year ending March 2019 to approximately ¥4.1 billion in the fiscal year ending March 2020.
  6. FY2018First statedAnnual report

    「For the fiscal year ending March 2019, we planned to spend approximately ¥4 billion on the acquisition of fixed assets, including the expansion of factory facilities.」

    A plan was announced to spend approximately ¥4 billion on factory expansion and other fixed assets in the fiscal year ending March 2019.
Moved together

"Strengthening the Ultra-Fast Gene Quantification Instrument Business through the Acquisition of Jitas" moved the same way as this thread, in the same document, in 2 of its 6 moves.

222★123
  1. ★This thread
  2. 1Strengthening the Ultra-Fast Gene Quantification Instrument Business through the Acquisition of Jitas2×
  3. 2Expanding the Generic Pharmaceutical Business Primarily through In-House Sales2×
  4. 3Activating the Drug Discovery Platform through Open Innovation and New Technologies2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.